Can a 're­dis­cov­ered' drug from In­dia make it big in US im­munol­o­gy space? Dan Brad­bury and his team at Equi­l­li­um want to prove yes

Biotech com­pa­nies typ­i­cal­ly knock on Nas­daq’s doors with sev­er­al rounds of fi­nanc­ing un­der their belt. Equi­l­li­um, how­ev­er, went straight for it.

Hav­ing reaped a $65.4 mil­lion IPO last month, the San Diego-based biotech is emerg­ing from stealth mode to dis­cuss for the first time that atyp­i­cal route — a some­what un­ex­pect­ed one, CEO Dan Brad­bury would add — and the atyp­i­cal arrange­ment that made it pos­si­ble for an op­er­a­tion that on­ly launched 18 months ago.

Equi­l­li­um li­censed North Amer­i­can rights to its one and on­ly drug, itolizum­ab, from In­di­an biosim­i­lar gi­ant Bio­con. Sold in In­dia as a pso­ri­a­sis treat­ment, the same drug has been rechris­tened EQ001 and is be­ing de­vel­oped for a num­ber of oth­er im­muno-in­flam­ma­to­ry dis­eases.

Brad­bury — who has known Bio­con founder Ki­ran Mazum­dar-Shaw since his days as CEO of di­a­betes drug­mak­er Amylin and cur­rent­ly sits on the Bio­con board — says Equi­l­li­um’s ap­proach is nov­el in the sense that re­cent ad­vances in im­munol­o­gy has al­lowed his team to “re­dis­cov­er” a prod­uct that was de­vel­oped in the 2000s to hit a tar­get, CD6, first dis­cov­ered in the 1980s.

In­hibit­ing CD6, new re­search has found, blocks ef­fec­tor T cell ac­tiv­i­ty with­out tam­per­ing with reg­u­la­to­ry T cells, a se­lec­tive ap­proach com­pared to some “brute force” bi­o­log­ics cur­rent­ly on the mar­ket, he says.

Bruce Steel

At the same time, he adds, since itolizum­ab is al­ready clin­i­cal­ly val­i­dat­ed and man­u­fac­tured at com­mer­cial scale, “it’s ac­tu­al­ly a fair­ly late-stage pro­gram rel­a­tive to many pro­grams that have gone pub­lic in the biotech­nol­o­gy space.”

Soon af­ter Equi­l­li­um li­censed the drug, Bio­con com­plet­ed “a large amount of work” need­ed to demon­strate that the prod­uct it was man­u­fac­tur­ing for Equi­l­li­um was bio­com­pa­ra­ble to what it was sell­ing on the mar­ket, as they are man­u­fac­tured on dif­fer­ent cell lines. It al­so wrapped a Phase I study for both sub­cu­ta­neous and IV forms of EQ001 in Aus­tralia (though part of the tri­al was ter­mi­nat­ed ear­ly, ac­cord­ing to the S-1) and got a thumbs up from the FDA re­gard­ing the man­u­fac­tur­ing fa­cil­i­ty it’s us­ing to make biosim­i­lars to be sold in the US — all good news for Equi­l­li­um.

That’s prob­a­bly part of what at­tract­ed the en­cour­age­ment from pub­lic in­vestors, many of whom had al­so worked with Brad­bury be­fore Amylin was sold to Bris­tol-My­ers Squibb for $5.3 bil­lion. The oth­er part? All the clin­i­cal plans lined up for 2019: Phase Ib/II aGVHD tri­al ear­ly on; Phase II cGVHD tri­al in H1; and proof-of-con­cept in se­vere asth­ma, with a goal to choose an ad­di­tion­al in­di­ca­tion be­fore wrap­ping up the year.

All told, the cash run­way should ex­tend to the next 24 months af­ter go­ing pub­lic at $14, the low end of the range. The stock has edged up, though, and is now rid­ing above $15 per share. The mar­ket cap is a mod­est $277 mil­lion.

Stephen Con­nel­ly

And Equi­l­li­um can do all this with­out wor­ry­ing about man­u­fac­tur­ing: Aside from a 13.9% stake in the com­pa­ny, Bio­con isn’t charg­ing any­thing for sup­ply­ing itolizum­ab for test­ing in up to three or­phan in­di­ca­tions. Pro­duc­tion cost of ad­di­tion­al prod­ucts, the $30 mil­lion promised in reg­u­la­to­ry mile­stones and $565 mil­lion sales pay­ments won’t be due un­til — or if — Equi­l­li­um nabs its first ap­proval in the US.

Mean­while, Brad­bury adds, Equi­l­li­um’s “small but mighty” team of 11 is still on the hunt for ad­di­tion­al as­sets to beef up its im­munol­o­gy pipeline.

Brad­bury and Bruce Steel, a co-founder of the com­pa­ny now serv­ing as pres­i­dent and CBO, own the largest chunks of stocks at 22.1% each. Stephen Con­nel­ly — co-founder, CSO and Steel’s for­mer col­league at Bio­Med Ven­tures — is in for 7.7%.


Im­age: Dan Brad­bury. EQUI­L­LI­UM

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

After spending most of the pandemic on the sidelines, Novartis is offering its aid in the race to develop a Covid-19 vaccine.

AveXis, the Swiss pharma’s gene therapy subsidiary, has agreed to manufacture the vaccine being developed by Massachusetts Eye and Ear and Massachusetts General Hospital. The biotech will begin manufacturing this month, while the vaccine undergoes further preclinical testing. They’ve agreed to provide the vaccine for free for clinical trials beginning in the second half of 2020, but have not disclosed financials for after.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.